Announcements Trials
Browse Landscape

Phase

Phase 1 39Phase 2 33Phase 1/2 11Phase 3 6Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 6Active not recruiting 3Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 5OTHER_GOV 1

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 5Sarcoma 1

Conditions

Melanoma 5Neoplasms 3Sarcoma 1Neoplasm Metastasis 1Fever 1

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Completed × trametinib × Clear all
NCT03784014 2026-04-29

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Completed
603 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma

NCT01682083 2026-04-21

COMBI-AD

Novartis

Phase 3 Completed
870 enrolled 15 charts 1 FDA
Dermatologic

Melanoma, Neoplasms

NCT03551626 2025-04-29

COMBI-APlus

Novartis

Phase 3 Completed
552 enrolled 12 charts
Dermatologic

Fever, Melanoma

NCT01597908 2021-02-24

COMBI-v

Novartis

Phase 3 Completed
704 enrolled 13 charts
Dermatologic

Melanoma, Neoplasms

NCT01584648 2021-02-17

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Novartis

Phase 3 Completed
423 enrolled 15 charts
Dermatologic

Melanoma

NCT01245062 2018-04-05

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

GlaxoSmithKline

Phase 3 Completed
322 enrolled 24 charts
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡